For Research Purposes Only — This compound is not FDA approved.

Catalog
GLP-3 (RT)
Metabolic Research

GLP-3 RT (Retatrutide)

Retatrutide (catalogue designation GLP-3 RT) is a 39-amino acid triple receptor peptide targeting the GLP-1, GIP, and glucagon pathways. Studied for metabolic-regulation and energy-balance signaling in research models. Premium Research Peptide.

Amount
Quantity
1
Bundle & Save
COA
Only 42 left in stock 18 people viewing now
Est. delivery in 2–5 business days
Free shipment protection
Overnight shipping available

Certificate of Analysis

Third Party Tested Freedom Diagnostics
99.85%
Purity · HPLC-UV
Latest BatchLC-MS IdentityUS Tested
Passed QC panel
Lot RT10-001Tested Jul 16, 2026
Purity (HPLC-UV)99.85%
Net Peptide Content12.85mg
Identity (LC-MS)GLP RT
Endotoxin (USP <85>)Pass · ≤0.05 EU/mL
Freedom Diagnostics · Independent third-party lab View full COA

Compound Information

Technical specifications
Molecular Profile

What is GLP-3 RT (retatrutide)?

CompoundRetatrutide
TypeSynthetic peptide
CAS Number2381089-83-2
Molecular Weight4,731 g/mol
Amino Acids39
Fatty Acid ChainC20 diacid
PubChem Database Retatrutide Research Guide
Storage Requirements

Stability Information

Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
−20°C · 24+ months
Reconstituted
2–8°C · ~30 days

Research Background

For laboratory research use only

What retatrutide is

Retatrutide, listed in this catalogue as GLP-3 RT, is a synthetic 39-amino-acid peptide with a molecular weight of about 4,731 g/mol. It is described in the literature as a triple agonist: a single molecule engineered to activate three related receptors, those for GIP, GLP-1 and glucagon. Dual agonists such as tirzepatide act on the first two; the glucagon receptor is what the third arm adds, and it is the reason the compound is studied separately rather than as a variation on earlier incretin peptides.

Three structural features do most of the work. The backbone is derived from the GIP sequence. Several positions carry non-coded amino acids, including two aminoisobutyric acid (Aib) residues, which protect the peptide from the DPP-4 enzyme that degrades native incretins within minutes. And a C20 fatty diacid is attached through a linker to a lysine side chain, so that the molecule binds serum albumin. That lipidation is what gives the compound its long residence time in pharmacokinetic studies, and it also changes how the material behaves on the bench.

What the published literature has examined

  • Receptor pharmacology. In vitro assays measuring cAMP signalling at each of the three receptors, used to characterise the balance of activity between them.
  • Energy balance in animal models. Rodent studies separating reduced food intake from increased energy expenditure, the second being the effect attributed to glucagon-receptor engagement.
  • Hepatic lipid handling. Preclinical work on liver fat content, again a question tied to the glucagon component.
  • Clinical development. The molecule has been studied in human trials by its originator, with phase 2 results published in peer-reviewed journals. Those trials used pharmaceutical-grade product made under GMP.

This research-grade material is not that pharmaceutical product. It is not a medicine, has not been evaluated for safety in people, and is supplied for in vitro and laboratory work only. The retatrutide research guide covers the literature in depth, and retatrutide vs tirzepatide sets the triple and dual agonists side by side.

How this material is characterised

A 39-residue lipidated peptide with non-coded amino acids is a demanding synthesis, and the typical impurities are close relatives of the target: deletion sequences missing one residue, or species lacking the fatty-acid chain. That is why the Certificate of Analysis above reports more than one measurement. HPLC-UV purity shows how much of the peptide signal is the main peak. LC-MS identity confirms that the main peak has the mass of retatrutide rather than a near neighbour. Net peptide content gives the actual peptide mass in the vial, which is the number to use for concentration calculations, and the endotoxin result matters for any cell-based assay. HPLC vs mass spectrometry explains why neither method is sufficient alone, and how to read a Certificate of Analysis walks through each line.

Handling in the laboratory

Lipidated peptides behave differently from simple ones. The fatty-acid chain makes the molecule surface-active: it can adsorb to glass and plastic at low concentrations, and it foams if shaken. Reconstitute by letting the solvent run down the vial wall and swirling gently. Keep the lyophilised powder frozen, dry and away from light; once in solution, refrigerate, use within weeks, and divide into single-use aliquots instead of freezing and thawing a stock repeatedly. For very dilute working solutions, low-binding tubes reduce losses to the container. See peptide storage and stability and how to reconstitute a research peptide.

Common questions

Is GLP-3 RT the same compound as retatrutide?

Yes. GLP-3 RT is the catalogue designation used on this site for retatrutide, CAS number 2381089-83-2. The LC-MS identity result on the Certificate of Analysis confirms the molecular mass for each lot.

Why is retatrutide called a triple agonist?

Because the single peptide activates three receptors in in vitro assays: the GIP receptor, the GLP-1 receptor and the glucagon receptor. Dual agonists such as tirzepatide act on the first two only.

Is this the same as the pharmaceutical product used in clinical trials?

No. Clinical trials use pharmaceutical-grade product manufactured under GMP by the originator. This is research-grade material for in vitro and laboratory use only. It is not a medicine and is not for human or veterinary use.

What does the C20 fatty diacid do?

It is a lipid chain attached to a lysine side chain through a linker. It lets the peptide bind serum albumin, which extends its residence time in pharmacokinetic studies. On the bench it also makes the peptide surface-active, so it can foam and adsorb to container walls.

How should lyophilised retatrutide be stored?

Keep the lyophilised powder at -20 C, dry and protected from light. After reconstitution store at 2-8 C, avoid repeated freeze-thaw cycles and aliquot into single-use volumes where the protocol allows.

Frequently Researched Together

Important Research Notice

Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.

By purchasing, you confirm that you are a qualified researcher and will use these products in accordance with all applicable laws and regulations.